Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 837, Issue 1-2, 2006, Pages 49-58

  van den Broek, I ^a   Sparidans, R W ^a   Huitema, A D R ^b   Schellens, J H M ^a   Beijnen, J H ^a,b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Enfuvirtide; HIV fusion inhibitor; LC MS MS; Peptide; Tifuvirtide

Indexed keywords

CONCENTRATION (PROCESS); COPOLYMERIZATION; ENZYME INHIBITION; FUSION REACTIONS; IMMUNOLOGY; METABOLITES; POLYPEPTIDES; VIRUSES;

ENFUVIRTIDE; HIV-FUSION INHIBITOR; LC-MS/MS; PEPTIDES; TIFUVIRTIDE;

BIOASSAY;

ACETONITRILE; COPOLYMER; DRUG METABOLITE; ENFUVIRTIDE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; M 20; TIFUVIRTIDE; UNCLASSIFIED DRUG; VINYL DERIVATIVE; WATER;

ANALYTIC METHOD; ARTICLE; CALIBRATION; DIAGNOSTIC ACCURACY; DRUG ISOLATION; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; PARTICLE SIZE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SEPARATION TECHNIQUE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33744502918     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2006.03.059     Document Type: Article

References (35)

1. Zhang X., Nieforth K., Lang J.M., Rouzier-Panis R., Reynes J., Dorr A., Kolis S., Stiles M.R., Kinchelow T., and Patel I.H. Clin. Pharm. Ther. 72 (2002) 10
2. Cooper D.A., and Lange J.M.A. Lancet Infect. Dis. 4 (2004) 426
3. Dando T.M., and Perry C.M. Drugs 63 (2003) 2755
4. Jamjian M.C., and McNicholl I.R. Am. J. Health Syst. Pharm. 61 (2004) 1242
5. Castagna A., Biswas P., Beretta A., and Lazzarin A. Drugs 65 (2005) 879
6. Patel I.H., Zhang X., Nieforth K., Salgo M., and Buss N. Clin. Pharmacokinet. 44 (2005) 175
7. Lalezari J.P., Patel I.H., Zhang X., Dorr A., Hawker N., Siddique Z., Kolis S.J., and Kinchelow T.J. J. Clin. Virol. 28 (2003) 217
8. Hardy H., and Skolnik P.R. Pharmacotherapy 24 (2004) 198
9. Eron J.J., Gulick R.M., Bartlett J.A., Merigan T., Arduino R., Kilby J.M., Yangco B., Diers A., Drobnes C., DeMasi R., Greenberg M., Melby T., Raskino C., Rusnak P., Zhang Y., Spence R., and Miralles G.D. J. Infect. Dis. 189 (2004) 1075
10. Lalezari J.P., Bellos N.C., Sathasivam K., Richmond G.J., Cohen C.J., Myers R.A., Henry D.H., Raskino C., Melby T., Murchinson H., Zhang Y., Spence R., Greenberg M.L., DeMasi R.A., and Miralles G.D. J. Infect. Dis. 191 (2005) 1155
11. R. Gulick, J. Eron, J.A. Bartlett, T. Merigan, B. Yangco, J. Kilby, P. Rusnak, J. Hui, R. DeMasi, A. Diers, B. Spence, F. Duff, G. Miralles, in: Interscience Conference on Antimicrobial Agents and Chemotherapy, 42nd congress, San Diego, CA, 27-30 September 2002. Abstract H-1075.
12. Martin-Carbonero L. AIDS Rev. 6 (2004) 61
13. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., and Matthews T.J. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9770
14. Lawless M.K., Barney S., Guthrie K.I., Bucy T.B., Petteway S.R., and Merutka G. Biochemistry 35 (1996) 13697
15. Esté J.A. Curr. Med. Chem. 10 (2003) 1617
16. http://www.emea.eu.int/humandocs/PDFs/EPAR/fuzeon/169503en6.pdf, Scientific discussion for the approval of Fuzeon, European Medicines Agency (EMEA), 2005.
17. http://www.rocheuk.com/ProductDB/Documents/rx/spc/fuzeon_SPC.pdf, Summary of product characteristics; Fuzeon, Roche registration Ltd, UK 2005.
18. Celli N., Gallard A.M., Rossi C., Zucchetti M., D'incalci M., and Rotilio D. J. Chromatogr. B 731 (1999) 335
19. Pereira A.S., DiLeone L., Souza F.H., Lilla S., Richter M., Schwartsmann G., and De Nucci G. J. Chromatrogr. B 816 (2005) 321
20. Shin B.S., Kim J., Yoon C.H., Kim C.H., Park E.H., Han J.W., and Yoo S.D. Rapid Commun. Mass Spectrom. 19 (2005) 408
21. Li Z., and Chan K.K. J. Pharm. Biomed. Anal. 22 (2000) 33
22. Feng W.Y., Chan K.K., and Covey J.M. J. Pharm. Biomed. Anal. 28 (2002) 601
23. Chavez-Eng C.M., Schwartz M., Constantzer M.L., and Matuszewski B.K. J. Chromatogr. B 721 (1999) 229
24. Stokvis E., Rosing H., López-Lázaro L., Jimeno J.M., Supko J.G., Schellens J.H.M., and Beijnen J.H. J. Mass Spectrom. 37 (2002) 992C
25. Tuthill C.W., Rudolph A., Li Y., Tan B., Fitzgerald T.J., Beck S.R., and Li Y.X. AAPS Pharm. Sci. Tech. 1 (2000) Article 11
26. Lawless M.K., Hopkins S., and Anwer K. J. Chromatogr. B 707 (1998) 213
27. Chang D., Kolis S.J., Linderholm K.H., Julian T.F., Nachi R., Dzerk A.M., Lin P.P., Lee J.W., and Bansal S.K. J. Pharm. Biomed. Anal. 38 (2005) 487
28. Dai S., Song H., Dou D., Qian X., Zhang Y., Cai Y., Liu X., and Tang Z. Rapid Commun. Mass Spectrom. 19 (2005) 1273
29. Edelhoch H. Biochemistry 6 (1967) 1948
30. Pace C.N., Vajdos F., Fee L., Grimsley G., and Gray T. Protein Sci. 4 (1995) 2411
31. http://www.fda.gov/cder/guidance/4252fnl.htm, Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP, May 2001.
32. Gagliardi L.G., Castells C.B., Ràfols C., Rosés M., and Bosch E. J. Chromatogr. A 1077 (2005) 159
33. García M.C. J. Chromatogr. B 825 (2005) 111
34. Apffel A., Fischer S., Goldberg G., Goodley P.C., and Kuhlmann F.E. J. Chromatogr. A 712 (1995) 177
35. Huber C.G., and Premstaller A. J. Chromatogr. A 849 (1999) 161